Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Enterprise Value history runs 14 years deep, the most recent figure standing at -$762.2 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 19.72% year-over-year to -$762.2 million; the TTM figure through Mar 2026 stood at -$762.2 million (down 19.72% YoY), while the FY2025 annual figure was -$874.7 million, down 21.89% from the prior year.
• Enterprise Value for Q1 2026 stood at -$762.2 million, up from -$874.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$161.2 million in Q2 2022, with the low at -$874.7 million in Q4 2025.
• The 5-year median for Enterprise Value is -$490.9 million (2025), against an average of -$510.2 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 140.65% in 2024, then jumped 34.83% in 2025.
• Viridian Therapeutics, Inc.\DE's Enterprise Value stood at -$424.6 million in 2022, then declined by 12.44% to -$477.4 million in 2023, then sank by 50.32% to -$717.6 million in 2024, then slipped by 21.89% to -$874.7 million in 2025, then increased by 12.86% to -$762.2 million in 2026.
• Business Quant data shows VRDN's Enterprise Value at -$762.2 million in Q1 2026, -$874.7 million in Q4 2025, and -$490.9 million in Q3 2025.